Volume | 2,348,860 |
|
|||||
News | (1) | ||||||
Day High | 2.65 | Low High |
|||||
Day Low | 2.51 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Cronos Group Inc | CRON | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.51 | 2.51 | 2.65 | 2.59 | 2.50 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
5,811 | 2,348,860 | US$ 2.61 | US$ 6,129,526 | - | 1.64 - 2.99 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:46:06 | 8 | US$ 2.58 | USD |
Cronos Group Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.35B | 381.30M | - | 88.27M | -73.96M | -0.19 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cronos News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRON Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.37 | 2.65 | 2.17 | 2.41 | 3,217,716 | 0.22 | 9.28% |
1 Month | 2.60 | 2.99 | 2.17 | 2.59 | 3,813,262 | -0.01 | -0.38% |
3 Months | 2.14 | 2.99 | 1.89 | 2.41 | 3,069,016 | 0.45 | 21.03% |
6 Months | 1.77 | 2.99 | 1.71 | 2.24 | 2,515,791 | 0.82 | 46.33% |
1 Year | 1.75 | 2.99 | 1.64 | 2.13 | 2,246,480 | 0.84 | 48.00% |
3 Years | 8.28 | 9.42 | 1.64 | 3.66 | 2,190,590 | -5.69 | -68.72% |
5 Years | 16.41 | 17.99 | 1.64 | 6.87 | 3,594,545 | -13.82 | -84.22% |
Cronos Description
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann. |